1 Profiling small RNAs in CRC screening samples such as

2 the widely used fecal immunochemical test, is it possible?

- 3 Einar Birkeland¹*, Giulio Ferrero^{2,3}*, Barbara Pardini^{4,5}, Sinan U. Umu⁶, Sonia Tarallo^{4,5}, Sara
- 4 Bulfamante⁷, Geir Hoff^{8, 9}, Carlo Senore⁷, Trine B Rounge^{10,11*}, Alessio Naccarati^{4,5*}
- 5 *Equal contributions
- 6

7 Affiliations

- 8 1. Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.
- 9 2. Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy.
- 10 3. Dept. of Computer Science, University of Turin, Turin, Italy.
- 11 4. Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Turin, Italy.
- 12 5. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
- 13 6. Department of Pathology, Institute of Clinical Medicine, University of Oslo, Norway
- 14 7. Epidemiology and Screening Unit-CPO, University Hospital Città della Salute e della
- 15 Scienza, Turin 10100, Italy.
- 16 8. Section for colorectal cancer screening, Cancer Registry of Norway, Oslo University
- 17 Hospital, Norway
- 18 9. Dept of Research, Telemark Hospital, Skien, Norway
- 19 10. Department of Research, Cancer Registry of Norway, Oslo, Norway.
- 20 11. Centre for Bioinformatics, Department of Pharmacy, University of Oslo, Oslo, Norway.
- 21
- 22 Corresponding authors: Trine B Rounge, <u>trinro@uio.no</u> and Alessio Naccarati,
 23 <u>alessio.naccarati@iigm.it</u>

24

Keywords: Small RNA sequencing, Fecal Immunochemical Test (FIT), colorectal cancer
 Screening, stoopplonger, that has not been cartified by page review and should not be used to guide clinical practice.

27 Abstract

28 Faecal microRNAs represent promising molecules with potential clinical interest as non-29 invasive diagnostic and prognostic biomarkers for their stability and detectability. Colorectal 30 cancer (CRC) screening based on the fecal immunochemical test (FIT) is an effective tool for 31 prevention of cancer development. However, due to the poor sensitivity of FIT for premalignant 32 lesions, there is a need for implementation of complementary tests. Improving the identification 33 of individuals who would benefit from further investigation with colonoscopy using molecular 34 analysis, such as miRNA profiling of the FIT leftover buffer, would be ideal due to its 35 widespread use.

In the present study, we applied small RNA sequencing to FIT leftover samples collected from two European screening populations. We showed robust detection of miRNA and microbial profiles, which were similar to those obtained from specimens sampled using RNA stabilising buffers and archived fecal samples. Detected miRNAs exhibited differential abundance between CRC and control samples that was consistent between sampling methods, suggesting a promising potential to identify small RNA CRC biomarkers using FIT leftovers.

42 We demonstrated that it is possible to analyse gut miRNAs in FIT leftover samples and 43 envision that these potential biomarkers can complement the FIT in large scale screening 44 settings.

45

46 Introduction

47 Colorectal cancer (CRC) is the third most common malignancy and the second leading cause 48 of cancer-related deaths(1). The promotion of healthy lifestyles and dietary choices, the 49 development of new strategies for disease management, and the implementation of global 50 screening programs are some of the strategies to reduce CRC morbidity and mortality.

51 Screening selected age groups at risk is considered the most effective tool to prevent CRC 52 development by detecting early tumor forms and precancerous lesions(2). In many European 53 countries, the first step of CRC screening relies on non-invasive stool-based tests such as 54 fecal immunochemical test (FIT). If the test is positive, patients are invited to visual 55 examinations based on invasive endoscopic methods, such as colonoscopy. The advantage 56 of first-line FIT is the relatively low-cost and ease of execution compared to colonoscopy. The 57 FIT does not require specific preparation or dietary restriction and consequently has high 58 acceptance rates. However, due to its poor sensitivity for premalignant lesions and the burden 59 associated with an excessive number of colonoscopy procedures, different countries adopt 60 thresholds for FIT positivity that are suited to their colonoscopy capacity, in a balancing act 61 between sensitivity and specificity.

62 This highlights the need for alternative biomarkers to improve CRC screening accuracy. The 63 implementation of complementary tests based on the analysis of the leftover of FIT stool 64 samples could help improve in the identification of those individuals that would benefit from 65 further investigation by colonoscopy. Both observational and experimental evidence point to 66 a role for the gut microbiome in development and progression of CRC (3). We have shown 67 that it is possible to profile the microbiome in FIT leftover samples and archived stool samples 68 (4). However, larger discovery studies are needed to identify clinically valuable biomarkers(5). 69 Small noncoding RNAs (sRNAs), particularly microRNAs (miRNAs), are detectable and stable 70 in stool samples and are emerging as a candidate source of biomarkers for the non-invasive 71 diagnosis of gastrointestinal diseases, including CRC(6). Using small RNA sequencing, we 72 demonstrated the possibility to quantify the levels of both human and microbial sRNAs in 73 human stool samples. Interestingly, the combined use of human and microbial sRNA levels 74 was more efficient than using the two biomarkers alone in classifying CRC patients from 75 colonoscopy-negative control subjects(7).

While we have shown that gut derived miRNAs are potential biomarkers for CRC, little is known about the possibility of measuring them in a screening population by using the FIT buffer leftovers. In this study, carried out in two independent European laboratories, we

showed not only the feasibility of small RNA sequencing in FIT samples but we also tested the profiling robustness by comparing sequencing data in FIT samples with feces collected in stabilising buffers and long term archived fecal samples. In addition, we showed that some gut miRNAs differed in abundance between CRC and controls, suggesting a potential for discovering CRC biomarkers.

84 Material and Methods

85 Cohorts and samples

BCSN - FIT: Bowel Cancer Screening in Norway (BCSN) is an ongoing (2012-) randomized trial comparing once-only sigmoidoscopy with repeated FIT tests every second year for up to four rounds. The study is a pilot for the national screening program(8). Stool samples are collected on plastic sticks designed to catch about 10µg stool and then stored in a 2ml buffer (Eiken Chemicals Ltd., Tokyo, Japan). Thirteen FIT samples from anonymized subjects were randomly selected for the purpose of this feasibility study.

92 NORCCAP - stool: The Norwegian Colorectal Cancer Prevention (NORCCAP) screening trial 93 was carried out from 1999 to 2001(9). Participants were asked to bring a fresh frozen stool 94 specimen collected at home less than one week before sigmoidoscopy and to keep in a 20ml 95 vial in their home deep freezer (-20°C) until attendance for flexible sigmoidoscopy. Eleven 96 anonymized stool samples were randomly selected.

97 **MITOS - FIT and stool:** The Italian biological samples have been collected in the frame of the regular Piedmont Region CRC screening in the Microbiome and MiRNA in Torino Screening 98 99 project (MITOS). The Piedmont Region screening program invites all residents, aged 59-69 to 100 undergo a single sample biennial FIT (Eiken Chemicals Ltd., Tokyo, Japan). A total of 185 101 subjects (based on colonoscopy results classified in 22 CRC, 80 advanced adenoma (AA), 30 102 non-advanced adenoma (nAA), and 53 controls) were included in the present study. Among 103 them, 57 subjects also provided stool samples collected in nucleic acid collection and transport 104 tubes with RNA stabilising solution (Norgen Biotek Corp.) before undergoing colonoscopy.

1	05
---	----

106 small RNA extraction and library preparation

107 FIT stool samples were obtained from buffer leftovers contained in the original collection

- 108 device (approx. 1ml). NORCCAP feces was thawed and homogenized in a buffer (Omnigene-
- 109 GUT, DNAgenotek). For BCSN FIT and NORCCAP stool samples, RNA was extracted from
- 110 200µl buffer leftovers and buffer mix, respectively. RNA was purified using phenol-chloroform
- 111 phase separation and miRNeasy Mini Kit (cat. no. 217004, QIAgen).
- 112 For the MITOS cohort, total RNA from stool and FIT leftover samples was extracted using the
- 113 Stool Total RNA Purification Kit (Norgen Biotek Corp.) as previously described(7).

114 sRNA transcripts were converted into barcoded cDNA libraries with the NEBNext Multiplex

115 Small RNA Library Prep Set for Illumina following the NEBNext Multiplex Small RNA Library

116 Prep Protocol E7330 (Protocol E7330, New England BioLabs Inc., USA)(7, 10).

The size selection of purified RNA fragments for the MITOS cohort was performed as described in (7). For BCSN and NORCCAP samples the size selection was performed with a cut size optimized to cover RNA molecules from 17 to 47 nt in length. Small RNA libraries were indexed and sequenced on Illumina platforms.

121

122 **Bioinformatics and statistical analysis**

Quantification of reads mapping to miRBase v22.1 miRNA sequences was performed using the smrnaseq pipeline (<u>https://nf-co.re/smrnaseq</u>) with reads prefiltered using fastp and the *skip_mirdeep* option. Reads unmapped on these annotations were aligned against the human hg38 genome using Bowtie2 with *-very-sensitive-local* option. The human-unmapped reads were mapped against microbial genomes using Kraken 2 (v2.1.2) as described in(7).

Reads mapping to miRNAs were normalized and Differential Expression (DE) analyses were performed using the DESeq2. Differential abundance analysis of reads mapped to microbes was performed with SIAMCAT with default settings. For more details, see Supplementary Methods.

132 **Results and discussion**

133 Cohort and alignment statistics

Fecal samples collected with different sampling, storage, and processing procedures were analysed to identify stably expressed miRNAs with a potential to be used as CRC biomarkers (Figure 1A). From the MITOS cohort, two sample types were collected for each individual: stool samples collected in RNA-stabilising buffer, and leftover buffer derived from CRCscreening FIT samples. Two sets of anonymized Norwegian samples were also assessed: archived stool samples stored without stabilising buffer from the NORCCAP study, and leftover buffer from Norwegian CRC-screening FIT samples from the BCSN trial.

141 As reported in **Supplementary Table 1A** and **B**, a mean of 0.12% of small RNA sequencing 142 reads (range: 0.003-0.062%) were assigned to miRNAs in stool samples, while a mean of 143 0.15% reads from FIT leftovers were assigned to miRNAs (range:0.03-0.61%). Considering 144 10 as the minimum number of normalised reads to define a miRNA as detected, on average 63 (range: 32-235) and 41 (range: 16-191) miRNAs were detected in stool and FIT leftover 145 146 samples, respectively (Supplementary Table 1A-B). Still, when accounting for differences in 147 sequencing depth by rarefaction, no differences in the number of miRNAs detected were found between sampling groups (p>0.1). The stool miRNAs detected in the MITOS cohort samples 148 included most of the annotations observed in previous analyses performed on the same 149 150 samples analysed using a different pipeline(7).

151 For two FIT leftover samples, the small RNA sequencing was performed on libraries generated 152 from two different amounts of starting material (250 and 400 µl). Comparing the rate of miRNA-153 mapped reads, similar rates were observed (0.4-0.9% of mapped reads) with an average of 154 33 miRNAs (range: 31-34) detected in each experiment. No significant differences were 155 observed among the miRNA levels measured in such experiments and, as expected, the 156 levels of detected molecules were significantly correlated (rho=0.43-0.60, p<0.001) 157 (Supplementary Figure 1A and Supplementary Table 1C). The intra-individual correlation 158 between miRNA levels was higher than among different individuals (Supplementary Figure

1B). Taken together all fecal/FIT samples collected in all cohorts, t FIT leftover samples
differed systematically from stool samples (see PCA analysis in Figure 1B).

161 Since the 57 stool samples from the MITOS cohort were collected from the same subjects 162 donating FIT leftover samples, a paired comparative analysis was performed between the 163 miRNA levels measured in the two biospecimens. The analysis was focused on the levels of 164 23 miRNAs that were consistently identified across both stool and FIT samples (exceeding a 165 median of 10 normalised reads; Figure 1C and Supplementary Table 1D). These miRNAs 166 correspond well with the most abundant miRNAs in circulation, including miR-1246, -320, -21-167 5p,-1290,-148a-3p being among the top 10 abundant miRNAs in serum samples(11). As 168 reported in **Supplementary Table 1D**, 57% of these miRNAs were characterised by levels positively correlated (average rho=0.36, p<0.05) between the two biospecimens. Among 169 170 them, miR-4713-3p, miR-1246, and miR-192-5p were characterised by the highest correlation. 171 All the 23 miRNAs were also detected in the Norwegian cohorts (Figure 1C), despite the 172 different sampling, preservation, and RNA extraction procedures. Moreover, there was a 173 positive correlation between FIT and stool samples for the mean normalised abundance of 174 miRNAs (rho=0.78; Figure 1D), which was also found in the Norwegian samples (rho=0.52)

175 (Figure 1D and Supplementary Figure 1C).

176

177 miRNA differential expression in MITOS stool and FIT samples

178 DE analysis was performed between MITOS-stool and MITOS-FIT miRNA levels detected in 179 subjects with CRC or AA with respect to colonoscopy-negative subjects. Considering the 23 180 miRNAs detected in both biofluids, 12 were associated with significantly different levels in stool 181 samples from CRC/AA patients (adj. p<0.05; Supplementary Table 1E). Comparing 182 separately AA and CRC patients with colonoscopy-negative subjects, four and eight DE 183 miRNAs were observed, respectively. Two miRNAs (miR-192-5p, and let-7b-5p) were DE in 184 both comparisons. Conversely, four miRNAs were significantly more (let-7b-5p and miR-148a-3p) and less (miR-4451 and miR-11399) abundant in FIT leftover samples of CRC patients 185 186 with respect to colonoscopy-negative subjects (Supplementary Table 1F). The levels of the 187 23 miRNAs were characterised by a coherent difference in both MITOS-stool and MITOS-FIT
188 samples (rho=0.69, p<0.001) (Figure 1E-F).

Functional analysis of DE miRNA target genes showed the prevalence of terms related to cell cycle regulation and DNA-damage response for the targets of miRNAs with increased levels in CRC patients (**Supplementary Table 1G-H**). Conversely, targets of miRNAs decreasing in patient samples were enriched in processes related to apoptosis, unfolded protein stress response, and immune response (**Supplementary Table 1G-H**).

194 Microbial classification/diversity

195 After the identification of human miRNAs, the remaining reads were aligned against the human 196 genome and the subsequent unmapped reads were investigated for their microbial sRNA 197 content. This approach classified reads in the range of 36-40 nt, of which 38.5% and 37.4% 198 classified MITOS FIT were in the stool and samples, respectively. 199 Given the previous evidence on the concordance between microbial abundances estimated 200 by small RNA sequencing and metagenomic data(7), the human-unmapped sRNA-Seq reads 201 were used to infer the microbial abundance in our data. Overall, FIT samples displayed a 202 higher abundance of taxa belonging to the *Bacteroidetes* phylum, whereas stool samples were 203 dominated by Firmicutes (Figure 2A-B), with the composition of stool and FIT samples 204 differing significantly (PERMANOVA p < 0.05; Figure 2C). This could indicate a differential 205 sensitivity of bacteria to the buffer components in the FIT and NORGEN buffers, where the 206 former has a relatively high concentration of the potent antimicrobial compound sodium azide 207 (12). Still, at the species level, there was concordance between FIT and stool samples (Figure 208 2D). Within the MITOS study subjects, we assessed differences in microbial taxa between 209 colonoscopy-negative and either CRC, AA, or CRC/AA. Only one species - Filimonas lacunae 210 - was found to be significantly more abundant in stool samples collected from CRC cases than 211 in controls, with nominal significance also observed in FIT samples. Like for human miRNAs, 212 the direction and magnitude of differences in taxa abundance between CRC cases and

colonoscopy-negative subjects were consistent in stool and FIT samples (rho = 0.48, p
<0.001).

215 Conclusions

Taken together, our results show that by using small RNA sequencing we can profile both stool miRNAs and microbial taxa in the left-over FIT buffer used in CRC screening. The consistent levels of miRNAs between sampling methods suggest that FIT may be used for miRNA biomarker research in large scale screening settings. This feasibility study also confirms that the alterations in gut miRNA levels in CRC patients observed in FIT samples may be used to detect miRNAs in FIT as biomarkers to improve screening performance.

222 Ethics approval and consent to participate

223 For the MITOS cohort the study design and the informed consent were approved by the local

224 Ethics committee (AOU Città della salute e della Scienza di Torino, Italy). For the NORCCAP

and BCSN cohorts anonymized samples were used. This was approved by the Norwegian

- 226 Regional Ethics Committee South-East (REC) projects, S-98052 and 2011/1272,
- 227 respectively.

228

229 Availability of data and materials

230 The datasets used and/or analysed during the current study are available from the

- 231 corresponding author on reasonable request.
- 232

233 Competing interests

234 The authors declare that they have no competing interests

235

236 Funding

237 This work was supported by the Italian Institute for Genomic Medicine (IIGM) and Compagnia

di San Paolo Torino, Italy (to AN, BP, and ST). This project has received funding from the

European Union's Horizon 2020 research and innovation program under grant agreement No 825410 (ONCOBIOME project to AN, BP, and ST). The research leading to these results has received funding from AIRC under IG 2020 - ID. 24882 – P.I. Naccarati Alessio Gordon (to AN) and under IG2019 - ID. 23473 - P.I. Senore Carlo (to CS). This project also received funding from the Norwegian Cancer Society open call 2017 (190179) to TBR and 2018 (198048) to TBR and from the Cancer Registry of Norways funds to TBR.

- 245 Authors' contributions
- 246 Concept and design (TBR, AN);
- 247 Collection and assembly of the data (GH, TBR, AN, CS);
- 248 Experimental tasks, data analysis and interpretation (EB, GF, BP, SUU);
- 249 Provisions of study materials or patients (GH, CS, SB);
- 250 Manuscript writing (EB, GF, BP, TBR, and AN);
- 251 Manuscript editing (All);
- 252 Final approval of the version (All).
- 253

254 Acknowledgements

We would like to thank Jan Inge Nordby for performing laboratory analyses for the Norwegian samples and the sequencing service was provided by the Norwegian Sequencing Centre (https://www.sequencing.uio.no), a national technology platform hosted by Oslo University Hospital and the University of Oslo supported by the Research Council of Norway and the Southeastern Regional Health Authority.

260

261 References

262

Y. Xi, P. Xu, Global colorectal cancer burden in 2020 and projections to 2040. *Transl Oncol* 14, 101174 (2021).

- 265 2. M. Buskermolen *et al.*, Colorectal cancer screening with faecal immunochemical
 266 testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. *Bmj* 367,
 267 I5383 (2019).
- J. L. A. Vleugels, Y. Hazewinkel, P. Fockens, E. Dekker, Natural history of diminutive
 and small colorectal polyps: a systematic literature review. *Gastrointest Endosc* 85,
 1169-1176 e1161 (2017).
- T. B. Rounge *et al.*, Evaluating gut microbiota profiles from archived fecal samples.
 BMC Gastroenterol 18, 171 (2018).
- A. S. Kvaerner *et al.*, The CRCbiome study: a large prospective cohort study examining
 the role of lifestyle and the gut microbiome in colorectal cancer screening participants. *BMC Cancer* 21, 930 (2021).
- T. S. Francavilla A, Pardini B, Naccarati A, Fecal microRNAs as non-invasive
 biomarkers for the detection of colorectal cancer: a systematic review. *Minerva Biotecnologica* 31, 30-42 (2019).
- 279 7. S. Tarallo *et al.*, Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut
 280 Microbiome Composition in Stool Samples. *mSystems* 4 (2019).
- 8. M. M. Zhu *et al.*, Comparison of immunochemical and guaiac-based fecal occult blood
 test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis.
 J Dig Dis **11**, 148-160 (2010).
- M. Bretthauer *et al.*, Design, organization and management of a controlled population
 screening study for detection of colorectal neoplasia: attendance rates in the
 NORCCAP study (Norwegian Colorectal Cancer Prevention). *Scand J Gastroenterol* 37, 568-573 (2002).
- 288 10. G. Ferrero *et al.*, Small non-coding RNA profiling in human biofluids and surrogate
 289 tissues from healthy individuals: description of the diverse and most represented
 290 species. *Oncotarget* 9, 3097-3111 (2018).
- 291 11. S. U. Umu *et al.*, A comprehensive profile of circulating RNAs in human serum. *RNA*292 *Biol* 15, 242-250 (2018).

- 293 12. S. Zouiouich et al., Comparison of Fecal Sample Collection Methods for Microbial
- 294 Analysis Embedded within Colorectal Cancer Screening Programs. *Cancer Epidemiol*
- 295 Biomarkers Prev **31**, 305-314 (2022).

296

298 Figures:



Figure 1. A. Graphical representation of the study. B. PCA of samples based on mature miRNA read counts. C. Bar plot reporting, for each cohort and sample type, the average levels of the miRNAs associated with the highest levels in MITOS FIT-leftover samples. D. Mean normalised abundance of miRNAs in paired MITOS-FIT (x-axis) and MITOS-Stool (y-axis)

304 samples. Each point represents a miRNA coloured based on the Spearman correlation 305 coefficient for comparison of paired samples. Only miRNAs detected in at least 15% of each 306 sample type were included in this analysis. E. Scatterplot showing the log2FC of expression 307 computed considering MITOS-stool (x-axis) and MITOS-FIT-leftover (y-axis) miRNA levels in 308 samples from CRC patients with respect to those from colonoscopy-negative subjects. F. 309 Heatmap of the Z-score-normalised DE miRNA levels in MITOS-stool and MITOS-FIT-leftover 310 samples. Neg, colonoscopy negative subjects; AA, advanced adenoma; nAA, non-advanced 311 adenoma; CRC, colorectal cancer.



Figure 2. A-B. Classification of reads according to microbial taxa. Relative abundance of phyla
in FIT-leftover and stool samples from MITOS (A) and NOR (B) cohorts. C. Principal
coordinate (PCo) plot of FIT and stool samples (including unpaired samples). D. Mean relative
abundance of species in stool samples (x-axis) and FIT samples (y-axis), coloured according

- 317 to the Spearman's rho of the correlation between the relative abundances in paired FIT and
- 318 stool samples. The solid diagonal line represents equal abundance in either biospecimen type.